WebAims: The effect of the angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril-valsartan in patients with heart failure with preserved ejection fraction (HFpEF) remains unclear, and data on ARNI treatment in peritoneal dialysis (PD) patients are lacking. The present study was designed to assess the efficacy and safety of sacubitril-valsartan in patients with … WebJul 2, 2024 · The 2014 PARADIGM-HF trial found that HFrEF patients (LVEF ≤40%) treated with sacubitril-valsartan had reduced risk of cardiovascular mortality, heart failure …
The angiotensin receptor neprilysin …
WebMay 12, 2024 · The rate of the composite primary endpoint of cardiovascular death, heart failure hospitalization or outpatient development of heart failure was 10% lower in patients taking sacubitril/valsartan compared with those taking ramipril, falling short of the prespecified threshold of a 15% reduction required to demonstrate statistically significant … WebJan 9, 2024 · Phase 1/2, multiple ascending dose Paramount study of propionic acidemia (PA) candidate (mRNA-3927) is ongoing. ... First patients have been dosed in a Phase 1B trial of our heart failure treatment candidate, mRNA-0184. This first-in-human Phase 1B clinical trial is being conducted in patients with stable heart failure to evaluate its safety ... mayfair bookshop
PARAGON-HF Trial Overview - AJMC
WebAug 26, 2012 · An ongoing study in approximately 8000 patients with reduced ejection fraction heart failure, PARADIGM-HF (NCT01035255), will provide more comprehensive … WebJul 29, 2024 · PARAGON-HF follows the only positive Phase II trial in HFpEF, PARAMOUNT-HF, which demonstrated that sacubitril/valsartan reduced NT-proBNP (a biomarker of cardiac strain) to a greater extent than ... hers precise products inc